Document Type
Article
Publication Date
11-1-2022
Publication Title
British journal of cancer
Keywords
JGM, Child, Humans, Adult, Male, Translational Research, Biomedical, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms
JAX Source
Br J Cancer. 2022;127(9):1577-83.
Volume
127
Issue
9
First Page
1577
Last Page
1583
ISSN
1532-1827
PMID
36229581
DOI
https://doi.org/10.1038/s41416-022-02000-4
Abstract
Germ cell tumours (GCTs) are a heterogeneous group of rare neoplasms that present in different anatomical sites and across a wide spectrum of patient ages from birth through to adulthood. Once these strata are applied, cohort numbers become modest, hindering inferences regarding management and therapeutic advances. Moreover, patients with GCTs are treated by different medical professionals including paediatric oncologists, neuro-oncologists, medical oncologists, neurosurgeons, gynaecological oncologists, surgeons, and urologists. Silos of care have thus formed, further hampering knowledge dissemination between specialists. Dedicated biobank specimen collection is therefore critical to foster continuous growth in our understanding of similarities and differences by age, gender, and site, particularly for rare cancers such as GCTs. Here, the Malignant Germ Cell International Consortium provides a framework to create a sustainable, global research infrastructure that facilitates acquisition of tissue and liquid biopsies together with matched clinical data sets that reflect the diversity of GCTs. Such an effort would create an invaluable repository of clinical and biological data which can underpin international collaborations that span professional boundaries, translate into clinical practice, and ultimately impact patient outcomes.
Recommended Citation
Fonseca A,
Lobo J,
Hazard F,
Gell J,
Nicholls P,
Weiss R,
Klosterkemper L,
Volchenboum S,
Nicholson J,
Frazier A,
Amatruda J,
Bagrodia A,
Lockley M,
Murray M.
Advancing clinical and translational research in germ cell tumours (GCT): recommendations from the Malignant Germ Cell International Consortium. Br J Cancer. 2022;127(9):1577-83.
Comments
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.